These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2005-005168-94 Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer bad-data
Reported results Terminated 2006-004374-27 Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent) 2010-02-17 due-trials
Completed, but no date, and reported results Terminated 2006-005819-10 Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation -TIBROMUC- bad-data
Reported results Terminated 2007-006051-39 Pharmakokinetic investigation on the tissue penetration of moxifloxacin within the pericardial space 2012-03-28 due-trials
Reported results 2008-003392-40 Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN... 2011-06-24 due-trials
Reported results 2009-011088-35 Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS)... 2015-02-10 due-trials
Reported results Terminated 2010-018539-16 A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after a... 2018-10-31 due-trials
Reported results 2010-020299-42 A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD) 2017-02-15 due-trials
Reported results Terminated 2011-004361-32 Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study Wirksamkeit... 2016-02-02 due-trials
Completed, but no date, and reported results 2012-003750-89 A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy Placebo-kontrollierte, doppelblinde, ran... bad-data
Reported results 2012-004585-18 Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. Randomized, controlled study to compare the analgesic therapy with tape... 2016-09-30 due-trials
Listed as ongoing, but also has a completion date 2016-001030-94 Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory th... 2022-12-12 bad-data
Completed, but no date, and reported results 2017-003688-37 Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controlled,... bad-data
Ongoing 2019-001770-29 Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial (VIGILung) Viruslast gesteuerte Immunsuppression nach Lunge... not-yet-due
Ongoing 2020-000784-23 The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect) Die Effekte von Behandlungserwartung an Esketamin vs. Placebo bei akut... not-yet-due
Not reported 2020-001732-10 Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept study Ruxolitinib zur Behandlung von Covid-19 induziertem Lungenversagen ARDS ... 2021-07-30 due-trials
Ongoing 2021-000271-36 Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial Guselkumab in Patienten mit oralem Lichen-Planus – Eine offene, parallele, rando... not-yet-due
Ongoing 2021-002335-33 Inhaled ColiFin® in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial Inhaliertes ColiFin® in erwa... not-yet-due
Ongoing 2022-003584-18 Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia Tezepelumab (Anti-TSLP-mab) bei progressiver interstitieller Lungenfibrose mi... not-yet-due
Ongoing 2022-003797-23 Myeloperoxidase inhibition in patients with ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction not-yet-due